InterCure Ltd. (TSX: INCR.U, TASE: INCR)(dba Canndoc)(the “Company”) is pleased to announce that further to its confidential filing with the U.S. Securities and Exchange Commission (the “SEC“) of its 20F registration statement on April 20, 2021, it will publicly file its 20F registration statement the week of July 11. The Company has also applied to list its common shares (the “Common Shares“) on the NASDAQ Capital Market (“NASDAQ“) under the trading symbol “INCR”, pending the public filing of the 20F registration statement and the satisfaction of certain other conditions. The Company expects that the Common Shares will commence trading on the NASDAQ during the last week of July 2021.
The Company believes that NASDAQ listing will enable the Company to broaden its global exposure through the world’s largest capital market, enhancing shareholder value. The Company believes that the listing will provide current investors with additional liquidity and prospective investors with better access to one of the leading and profitable international cannabis companies outside of North America.
Listing on the NASDAQ is subject to satisfaction of all applicable listing and regulatory requirements, including registration of the Common Shares with the SEC, and NASDAQ requirements and approvals. Following receipt of all required approvals, the Company will issue a press release announcing its first trading day on the NASDAQ.